Boston Scientific Says Dead-End SEC Probe Sinks Stock Suit

By Brian Dowling · January 4, 2022, 4:50 PM EST

The U.S. Securities and Exchange Commission is not bringing securities claims against Boston Scientific for halting the production of its Lotus Edge heart device, the company said Monday as it sought...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Case Information

Case Title

In re Boston Scientific Corporation Securities Litigation

Case Number

Court

Massachusetts

Nature of Suit

Stockholders Suits

Date Filed

December 16, 2020

Recent Articles By Brian

November 15, 2024
Pharma Biz To Pay $47M To Settle Feds' Kickback Claims
October 15, 2024
Feds Cut Whistleblowers Out Of Kickback Deal, Court Told
October 09, 2024
Lead Test Maker Vows Compliance As $42M Deal Approved
October 07, 2024
Trio Of 1st Circ. Criminal Cases Turned Away By Top Court
October 02, 2024
Abortion Clinic To Get Early Discovery In Patient Spying Case
October 01, 2024
Mass. Hospital To Pay Up To $6.5M In Sober Home Scheme
September 30, 2024
Medical Device Co. Wins $25M Verdict In Poaching Trial
September 26, 2024
Behavioral Health Exec Pleads Guilty To Medical Billing Fraud
September 03, 2024
Aesthetic Laser Co. Tells Jury Of Rival's 'Corporate Raid'
July 31, 2024
1st Circ. Mostly Backs $5M Award In Biotech Recruiting Spat